Published On: Sat, Mar 11th, 2017

New Analyst Ratings On Ligand Pharmaceuticals Incorporated (LGND)


Recently stock market analysts have updated their consensus ratings on shares of Ligand Pharmaceuticals Incorporated (LGND).

Most recent broker ratings

11/21/2016 – Ligand Pharmaceuticals Incorporated had its “buy” rating reiterated by analysts at Roth Capital. They now have a USD 154 price target on the stock.

10/05/2016 – Ligand Pharmaceuticals Incorporated had its “buy” rating reiterated by analysts at H.C. Wainwright. They now have a USD 160 price target on the stock.

09/07/2016 – Ligand Pharmaceuticals Incorporated was upgraded to “hold” by analysts at Deutsche Bank. They now have a USD 105 price target on the stock.

04/13/2016 – Stephens began new coverage on Ligand Pharmaceuticals Incorporated giving the company a “overweight” rating. They now have a USD 150 price target on the stock.

03/11/2016 – Sidoti began new coverage on Ligand Pharmaceuticals Incorporated giving the company a “buy” rating. They now have a USD 140 price target on the stock.

06/19/2015 – Ligand Pharmaceuticals Incorporated had its “hold” rating reiterated by analysts at Cantor Fitzgerald. They now have a USD 93 price target on the stock.

05/20/2015 – Ligand Pharmaceuticals Incorporated had its “buy” rating reiterated by analysts at Craig-Hallum. They now have a USD 105 price target on the stock.

05/05/2015 – Ligand Pharmaceuticals Incorporated was downgraded to “sell” by analysts at Zacks.

03/03/2015 – Ligand Pharmaceuticals Incorporated was upgraded to “buy” by analysts at CRT Capital. They now have a USD 102 price target on the stock.

07/22/2014 – Empire Asset Management began new coverage on Ligand Pharmaceuticals Incorporated giving the company a “sell” rating. They now have a USD 16 price target on the stock.

04/28/2014 – Ligand Pharmaceuticals Incorporated was upgraded to “neutral” by analysts at Ned Davis Research.

03/24/2014 – Brinson Patrick began new coverage on Ligand Pharmaceuticals Incorporated giving the company a “outperform” rating.

02/24/2014 – Ligand Pharmaceuticals Incorporated had its “buy” rating reiterated by analysts at Summer Street. They now have a USD 91 price target on the stock.

02/13/2014 – Ligand Pharmaceuticals Incorporated was upgraded to “buy” by analysts at TheStreet.

02/13/2014 – Ligand Pharmaceuticals Incorporated had its “buy” rating reiterated by analysts at MLV & Co. They now have a USD 96 price target on the stock.

Ligand Pharmaceuticals Incorporated has a 50 day moving average of 105.11 and a 200 day moving average of 104.19. The stock’s market capitalization is 2.29B, it has a 52-week low of 87.50 and a 52-week high of 139.79.

The share price of the company (LGND) was up +0.96% during the last trading session, with a high of 109.59 and the volume of Ligand Pharmaceuticals Incorporated shares traded was 186082.

Ligand Pharmaceuticals Incorporated (Ligand) is a biopharmaceutical company that focuses on developing and acquiring technologies that help pharmaceutical companies discover and develop medicines. The Company is involved in the development and licensing of biopharmaceutical assets. The Company employs research technologies, such as nuclear receptor assays, high throughput computer screening, formulation science, liver targeted pro-drug technologies and antibody discovery technologies to assist companies in their work toward obtaining prescription drug approvals. As of December 31, 2016, it had partnerships and license agreements with over 85 pharmaceutical and biotechnology companies, and over 140 various programs under license with it were in various stages of commercialization and development. It has contributed research and technologies for approved medicines that treat cancer, osteoporosis, fungal infections and low blood platelets, among others.